471-29-4

Usage

Uses

Used in Pharmaceutical Industry:
Methylguanidine is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs with potential applications in treating various medical conditions.
Used in Chemical Synthesis:
In the chemical industry, methylguanidine is used as a reagent and building block for the synthesis of various organic compounds. Its ability to form stable complexes with other molecules makes it a valuable component in the creation of new chemical entities with diverse applications.
Used in Research and Development:
Methylguanidine is also utilized in research and development settings, where it serves as a model compound for studying the properties and reactivity of guanidine derivatives. This helps scientists understand the underlying mechanisms of various chemical reactions and develop new strategies for synthesizing complex molecules.

InChI:InChI=1/C2H7N3/c1-5-2(3)4/h1H3,(H4,3,4,5)

Upstream product

• 60-27-5 creatinine 
• 64-17-5 ethanol 
• 420-04-2 CYANAMID 
• 593-51-1 methylamine hydrochloride 
• 18805-25-9 methyl carbonimidodithioic acid dimethyl ester 
• 26758-00-9 1,7-dimethylguanine 
• 89532-01-4 N,N'-diacetyl-N''-methyl-guanidine 
• 1674-62-0 N₁-methyl biguanide hydrochloride 
• 156-62-7 calcium cyanamide 
• 22113-87-7 Monomethylammonium nitrate 
• 2986-19-8 carbamimidothioic acid methyl ester 
• 124-40-3 dimethyl amine 
• 4674-68-4 methylcyanamide 
• 113-00-8 guanidine nitrate 

Downstream Products

• 108084-81-7 N-methyl-N'-phenylazo-guanidine 
• 98141-16-3 4-Amino-2-methylamino-5-cyan-pyrimidin 
• 90559-06-1 1-methyl-3-benzoylguanidine 
• 101428-28-8 N-(bis-benzyloxy-phosphoryl)-N'-methyl-guanidine 
• 89181-81-7 6-amino-2-methylamino-3H-pyrimidin-4-one 
• 51093-34-6 2,6-diamino-1-methyl-4(1H)-pyrimidione 
• 106882-57-9 methylcarbamimidoyl-amidophosphoric acid diphenyl ester 
• 89181-81-7 4-Amino-6-hydroxy-2-methylamino-pyrimidin 
• 77307-78-9 1,6-Dimethyl-4,6-diphenyl-1,6-dihydro-pyrimidin-2-ylamine 
• 961-07-9 2'-Deoxyguanosine 
• 124762-93-2 2-Amino-1-methyl-4,5-dihydro-1H-imidazole-4,5-diol 
• 162604-92-4 2-N-methyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxy-α-ψ-isocytidine 
• 162604-85-5 2-N-methyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxy-β-ψ-isocytidine 
• 162604-90-2 2-N-methyl-2'-O-allyl-5'-O-(4,4'-dimethoxytrityl)-ψ-isocytidine 

Relevant academic research and scientific papers

Visible Light-Induced Aerobic Epoxidation of α,β-Unsaturated Ketones Mediated by Amidines

An aerobic photoepoxidation of α,β-unsaturated ketones driven by visible light in the presence of tetramethylguanidine (3b), tetraphenylporphine (H2TPP), and molecular oxygen under mild conditions was revealed. The corresponding α,β-epoxy ketones were obtained in yields of up to 94% in 96 h. The reaction time was shortened to 4.6 h by flow synthesis. The mechanism related to singlet oxygen was supported by experiments and density functional theory (DFT) calculations.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines

A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50 = 2.2 nM and 11d, IC50 = 3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia.

Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazinyl acylguanidine derivatives as potential cardiovascular agents

A series of novel Ligustrazinyl acylguanidines was designed, synthesized and evaluated for their protective effect on injured vascular endothelial cell (ECV-304). The preliminary results demonstrated that some compounds possessed more potent activities than that of Ligustrazine in stimulating replication of the injured endothelial cell. Among the active compounds, compounds 8b, 8f and 8l displayed remarkable antioxidative activity with low EC50 values of 0.097, 0.059 and 0.094 mM, respectively. Structure-activity relationships were briefly discussed.

Discovery and initial optimization of 5,5′-disubstituted aminohydantoins as potent β-secretase (BACE1) inhibitors

8,8-Diphenyl-2,3,4,8-tetrahydroimidazo[1,5-a]pyrimidin-6-amine (1) was identified through HTS, as a weak (micromolar) inhibitor of BACE1. X-Ray crystallographic studies indicate the 2-aminoimidazole ring forms key H-bonding interactions with Asp32 and Asp228 in the catalytic site of BACE1. Lead optimization using structure-based focused libraries led to the identification of low nanomolar BACE1 inhibitors such as 20b with substituents which extend from the S1 to the S3 pocket.

SUBSTITUTED 5,6-DIHYDRO-6-PHENYLBENZO[F] ISOQUINOLIN-2-AMINE COMPOUNDS

The present invention relates to substituted 5,6-dihydro-6- phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.

Reaction of thiourea dioxides with amines

The reaction mechanism of thiourea dioxides with ammonia and primary aliphatic amines involves direct nucleophile (ammonia or amine) reactions with thiourea dioxides, followed by dissociation of the resulting adduct to form the sulfoxylate ion. 2004 MAIK "Nauka/Interperiodica".

Synthesis of Guanidino-1,3,5-triazines Using DMF

2,4,6-Triguanidino-1,3,5-triazine and 2,4,6-tris(3-methylguanidino)-1,3,5-triazine were synthesized in 42 and 52percent yields, respectively, by the cyclotrimerization of cyanoguanidine and 1-methyl-3-cyanoguanidine using DMF as a solvent in the presence of hydrogen chloride. 1-Phenyl-3-cyanoguanidine, 1,2-dimethyl-3-cyanoguanidine, and 2-imidazolidinylidenecyanamide, however, were cyclodimerized to the corresponding guanidino-1,3,5-triazines in a similar manner.